Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD): exome sequencing of trios, monozygotic twins and tumours by unknown
RESEARCH Open Access
Rapid-Onset Obesity with Hypothalamic
Dysfunction, Hypoventilation, and
Autonomic Dysregulation (ROHHAD):
exome sequencing of trios, monozygotic
twins and tumours
Sarah F. Barclay1, Casey M. Rand2, Lauren A. Borch1, Lisa Nguyen1, Paul A. Gray3, William T. Gibson4,
Richard J. A. Wilson5, Paul M. K. Gordon1, Zaw Aung1, Elizabeth M. Berry-Kravis6, Diego Ize-Ludlow7,
Debra E. Weese-Mayer2,8† and N. Torben Bech-Hansen1*†
Abstract
Background: Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation
(ROHHAD) is thought to be a genetic disease caused by de novo mutations, though causative mutations have yet
to be identified. We searched for de novo coding mutations among a carefully-diagnosed and clinically
homogeneous cohort of 35 ROHHAD patients.
Methods: We sequenced the exomes of seven ROHHAD trios, plus tumours from four of these patients and the
unaffected monozygotic (MZ) twin of one (discovery cohort), to identify constitutional and somatic de novo sequence
variants. We further analyzed this exome data to search for candidate genes under autosomal dominant and recessive
models, and to identify structural variations. Candidate genes were tested by exome or Sanger sequencing in a
replication cohort of 28 ROHHAD singletons.
Results: The analysis of the trio-based exomes found 13 de novo variants. However, no two patients had de novo
variants in the same gene, and additional patient exomes and mutation analysis in the replication cohort did not
provide strong genetic evidence to implicate any of these sequence variants in ROHHAD. Somatic comparisons
revealed no coding differences between any blood and tumour samples, or between the two discordant MZ twins.
Neither autosomal dominant nor recessive analysis yielded candidate genes for ROHHAD, and we did not identify any
potentially causative structural variations.
Conclusions: Clinical exome sequencing is highly unlikely to be a useful diagnostic test in patients with true ROHHAD.
As ROHHAD has a high risk for fatality if not properly managed, it remains imperative to expand the search for
non-exomic genetic risk factors, as well as to investigate other possible mechanisms of disease. In so doing, we will be
able to confirm objectively the ROHHAD diagnosis and to contribute to our understanding of obesity, respiratory
control, hypothalamic function, and autonomic regulation.
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Background
Rapid-onset Obesity with Hypothalamic Dysfunction,
Hypoventilation, and Autonomic Dysregulation (ROH-
HAD) is a complex and devastating disease whose etiology
is poorly understood, despite its initial description 50 years
ago [1]. The condition, previously termed “late-onset cen-
tral hypoventilation syndrome with hypothalamic dysfunc-
tion” is extremely rare, with fewer than 100 cases reported
in the literature, and occurs sporadically, with no clear-cut
family history for inheritance of the phenotype [1–7]. In
addition to the hypothalamic, respiratory and autonomic
manifestations that are hallmarks of the disease, about
40 % of ROHHAD patients develop benign tumours of
neural crest origin [2–4]. Because of the heralding feature
of the rapid-onset obesity (20–30 lb over a 3–6 month
period in, typically, a 2–7 year old, otherwise healthy,
child), affected children should come to the attention of
their pediatricians early in the clinical course. However,
due to the variable timing and onset of other features,
coupled with the presumption of exogenous obesity, a
ROHHAD diagnosis is often delayed or missed, potentially
leading to fatal central hypoventilation, cardiorespiratory
arrest, and impaired neurocognitive development. Con-
versely, many children with marked and potentially rapid
weight gain, who do not meet the additional clinical cri-
teria for ROHHAD, are inappropriately labeled as having
ROHHAD. While diagnostic criteria and knowledge of
the disease course have improved since the introduction
of the ROHHAD acronym by Ize-Ludlow and coworkers
in 2007 [2], these issues remain a challenge. Thus, unam-
biguous diagnosis of ROHHAD is difficult but essential –
not only for scientific inquiry but also for appropriate
patient care. The identification of a diagnostic marker
(genetic or otherwise) has the potential to decrease mor-
bidity and mortality of patients with ROHHAD, and to
guide future intervention and research on this disease.
As many ROHHAD features are reminiscent of other
neurocristopathies of genetic origin, such as Congenital
Central Hypoventilation Syndrome (CCHS) [7], a genetic
basis to ROHHAD has been hypothesized. The sporadic
appearance of a syndrome with tumour predisposition
and an apparently primary disturbance of body growth
is consistent with somatic mosaicism or constitutional
inheritance of a de novo dominant mutation (as seen in
Sotos syndrome [8], Proteus syndrome [9], CLOVES syn-
drome [10], and Weaver syndrome [11]), though epigen-
etic mechanisms could also be postulated, as have been
shown to occur in Beckwith-Wiedemann syndrome [12].
However, previous candidate gene studies in ROHHAD
using Sanger sequencing have not revealed a clear candi-
date gene that can account for the full ROHHAD pheno-
type [2, 4, 13].
To date, most known disease-causing mutations have
been identified within the coding portion of the genome.
Whole exome sequencing (WES) among small, carefully-
phenotyped cohorts has proven to be a very effective
means of identifying the cause of rare pediatric diseases, a
fact well demonstrated in a large national exome sequen-
cing effort (FORGE Canada Consortium) that found
disease-causing variants for 146 rare pediatric diseases, in-
cluding variants in 67 genes not previously linked to any
human disease [14]. Thus, WES is a highly cost-effective
and efficient method for solving the genetic basis of rare
diseases. To search for both constitutional and somatic de
novo sequence variants that could be the cause of this se-
vere pediatric disease, we used WES to analyze seven
ROHHAD trios, the unaffected monozygotic (MZ) twin of
one of these seven patients, and tumours isolated from
four of these seven patients as a discovery cohort. We also
assembled a replication cohort of 28 singleton ROHHAD
cases in which to analyze candidate genes identified
through WES.
Methods
Criteria for preliminary diagnosis
The basic criteria for consideration of the diagnosis of
ROHHAD were published in Ize-Ludlow et al. (2007) [2].
Briefly, features included: 1) onset of rapid and extreme
weight gain after age 1.5 years (typically 2–7 years) in a pre-
viously non-obese and seemingly normal child, 2) evidence
of hypothalamic dysfunction, 3) alveolar hypoventilation,
and 4) features of autonomic dysregulation.
Patient selection
The Center for Autonomic Medicine in Pediatrics (CAMP)
at Ann & Robert H. Lurie Children’s Hospital of Chicago
and the Stanley Manne Children’s Research Institute is a
Center of Excellence for the study of ROHHAD. Medical
records for each proband referred to CAMP were reviewed
to confirm ROHHAD characteristics. Cases were then
tested and confirmed negative for any CCHS-related
PHOX2B gene mutations. All of the patients selected for
exome sequencing were evaluated clinically in the CAMP
laboratory for serial characterization of the ROHHAD
phenotype (control of breathing, hypothalamic dysfunc-
tion, and autonomic dysregulation). Patients who met strict
diagnostic criteria for ROHHAD were offered inclusion
into both the International ROHHAD REDCap Registry
and the ROHHAD Genetic Inquiry project (both IRB-
approved). In this cohort, all patients demonstrated rapid-
onset obesity, hypothalamic dysfunction, hypoventilation
requiring artificial ventilation, and autonomic dysregula-
tion. All (35) patients who consented to the Genetic
Inquiry project, provided a peripheral blood sample and,
where appropriate, provided a frozen neural crest tumour
tissue sample, were included in this study. All (7) patients
whose parents also consented to the Genetic Inquiry pro-
ject and provided a peripheral blood sample were included
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in the discovery cohort for trio analysis. The other 28 par-
ticipants formed the replication cohort, of which exome
sequence data were obtained for 9 and the remaining
19 were analyzed by Sanger sequencing, only in genes
of interest.
Ethics, consent and permissions
This study was approved by the Ann & Robert H. Lurie
Children’s Hospital of Chicago IRB (study ID: 2009–
13904) and the University of Calgary Conjoint Health
Research Ethics Board (study ID: REB13-0164_REN2).
All participants provided informed consent to partici-
pate, including consent to publish the data herein.
Sample collection and DNA extraction
Genomic DNA was isolated from blood and tumour sam-
ples, using a Puregene reagent kit (Qiagen). Tumours in-
cluded both ganglioneuroma and ganglioneuroblastoma
samples (Table 1).
Whole exome sequencing and analysis
Exome captures were completed using the Agilent Sure-
Select V5 + UTRs capture kit. Massively parallel sequen-
cing was performed on a SOLiD platform, at the Alberta
Children’s Hospital Research Institute (ACHRI), and se-
quences were aligned to the human reference genome
(GRCh37) using Lifescope Genomic Analysis Software
2.5 (Life Technologies), (see Table 2). Variants were
called using DeNovoGear [15] for the trio, twin, and
tumour analyses; and the Genome Analysis Toolkit
(GATK) Haplotype Caller (Version 3.3) [16] for the re-
cessive and dominant analyses; and annotated for filtra-
tion and prioritization using ANNOVAR [17]. For the
trio analysis, candidate variants were identified as novel
or rare (MAF < 0.005, according to 1000 Genomes Pro-
ject [18], the Exome Variant Server [EVS; [19]] and the
Exome Aggregation Consortium [ExAC; [20]]) exonic,
UTR, or splice site (within 2 bp of an exon) variants not
within a segmental duplication. Candidate variants were
further filtered to exclude UTR variants for the recessive
analysis, and both UTR and synonymous variants for the
dominant analysis. Candidate variants were assessed
using Combined Annotation Dependent Depletion
(CADD) [21] and PolyPhen-2 [22] (for non-synonymous
variants) to predict deleteriousness. CADD scores are
phred-scaled, so a score of 10 indicates the pathogenicity
score of a variant is in the top 10 % of the scores for all
possible human variants; a score of 20 indicates it is in
the top 1 % etc. PolyPhen-2 scores represent the prob-
ability that the variant is deleterious.
Structural variation analysis
Bellerophon v1.03 [23] was used with the default settings
to search for chromosomal translocation and inter-
chromosomal insertions located inside exons in all 16
ROHHAD proband exomes (the 7 discovery cohort trio
probands and the 9 replication cohort exomes) and 4
tumour samples. FishingCNV v2.1 [24] was used to
search for genomic copy number variants (CNVs) in the
seven trio ROHHAD probands within the discovery co-
hort. Exomes from 22 healthy individuals, sequenced
with the same enrichment kit (Agilent SureSelect cap-
ture kit V5 + UTRs), were used as controls. We used
Benjamini-Hochberg multiple testing correction to de-
tect CNVs with a p-value < 0.05.
Variant validation and mutation analysis by sanger
sequencing
The NCBI Primer Blast tool [25] was used to design site-
specific primers to amplify genomic regions of interest.
The amplicons were purified using the E.Z.N.A. Cycle
Pure spin purification protocol (Omega Biotek) and then
sequenced using the fluorescent dideoxy terminator
method (Sanger method). Amplicon sequences were com-
pared to the reference genome (GRCh37) using Mutation
Surveyor (SoftGenetics) in order to identify variant posi-
tions within the exons or UTRs. All de novo candidate var-
iants identified by DeNovoGear [15] with a posterior
probability of 0.9 or greater were validated in this way, as
were select candidate variants identified in the singleton
(autosomal dominant and autosomal recessive) analyses.
Selected candidate genes identified in the discovery cohort
of 7 ROHHAD probands underwent mutation analysis by
Sanger sequencing in 19 additional ROHHAD patients.
Table 1 Phenotype of probands with Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic































3.7 (1.8-8) 28/28 28/28 28/28 28/28 10/28
aTumors were ganglioneuromas or ganglioneuroblastomas of the chest and abdomen
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Table 2 Details of exome sequencing
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ACHRI (Agilent SureSelect V5 +
UTRs, Life Technologies SOLiD
5500xl, LifeScope 2.5)
18 Proband 141.4 132.7 (14.1) 91.88 931.79 (0.81)
31 Mother of 18 143.9 91.62
22 Father of 18 136 90.93
37 Monozygotic twin of 18 133.5 90.97
25 Proband 125.4 92.01
51 Mother of 25 149.6 92.81
50 Father of 25 151.2 92.84
27 Proband 139.2 91.87
32 Mother of 27 128 91.11
33 Father of 27 126.3 90.94
41 Proband 124.5 90.92
47 Mother of 41 142.1 92.97
46 Father of 41 139.4 92.65
42 Proband 133.4 92.04
43 Mother of 42 127.2 91.55
44 Father of 42 119.1 90.91
45 Proband 122.2 91.73
48 Mother of 45 136.3 92.43
49 Father of 45 165.1 93.58
57 Proband 124.7 91.45
59 Mother of 57 113.4 90.55
58 Father of 57 98.5 91.57
18 Tumour 257 249.8 (40) 94.74 95.11 (0.54)
27 Tumour 290.2 95.15
41 Tumour 258.3 95.85
57 Tumour 193.9 94.69
Replication
Cohort
WASH U (Illumina All Exon
65 MB, Illumina HiSeq 2000,
NovoAlign 2.07.13)
5 Proband 86.9 86.9 82.70 82.70
BGI (Agilent SureSelect V4,
Illumina HiSeq 2000, BWA 0.5.9)
20 Proband 27.6 28.1 (1.7) 50.41 50.95 (1.79)
21 Proband 31.7 54.78
23 Proband 27.8 49.96
24 Proband 27.2 50.70
26 Proband 27.8 51.12
28 Proband 28 50.53
39 Proband 26.4 49.18
Perkin Elmer Corp (Agilent
SureSelect Human All Exon
38 MB, Illumina HiSeq 2000,
Bowtie 0.12.7)
A032 Proband 76.6 76.6 65.96 65.96
aACHRI: Alberta Children’s Hospital Research Institute, Calgary, Canada; WASH U: Washington University, St. Louis, USA; BGI: Beijing Genome Institute,
Beijing, China
Barclay et al. Orphanet Journal of Rare Diseases  (2015) 10:103 Page 4 of 13
Mutation analysis by exome sequencing
WES was obtained for nine members of the ROHHAD
replication cohort, and was used to search for candidate
variants in the genes identified as potential candidates
through the analysis of the trio exomes (i.e., genes carrying
de novo or compound heterozygous variants in one of the
seven trios; or heterozygous, rare, protein-altering variants
in three of the seven trio probands). Exome captures were
completed using the Agilent SureSelect capture kit,
38 MB or V4, or the Illumina All Exon 65 MB kit. Mas-
sively parallel sequencing was performed on either a
SOLiD or Illumina platform, at one of three institutions,
and sequences were aligned to the human reference gen-
ome (GRCh37) using BWA 0.5.9 [26], Lifescope Genomic
Analysis Software 2.5 (Life Technologies), NovoAlign
2.07.13 (Novocroft), or Bowtie 0.12.7 [27] (see Table 2).
Variants were called using the GATK Haplotype Caller
(Version 3.3) [16] and annotated for filtration and
prioritization using ANNOVAR [17]. The coverage of
these nine exomes was not sufficient for a robust whole
exome analysis (Table 2), but provided a reasonable data
set in which to perform an exploratory mutation analysis
(Additional file 1 shows the low-coverage proportions for




A total of 35 ROHHAD patients in whom the clinical
diagnosis was confirmed were included in this cohort for
genetic investigation (Table 1). Specifically, 7 of these pa-
tients were included in the initial, trio-based, exome se-
quencing analysis (discovery cohort), while 28 other
ROHHAD patients were included in the secondary ex-
ome and Sanger sequencing analysis (replication cohort).
In addition, neural crest tumours from four ROHHAD
patients (all of whom were trio probands) were analyzed.
Blood DNA from 14 parents of the probands (7 trios)
and from the monozygotic twin of one ROHHAD pro-
band (discordant for the ROHHAD phenotype) was also
included in our analysis. Our cohort represents a highly
homogeneous group of ROHHAD patients, and all of
the 35 patients included in the study showed rapid-onset
obesity, hypothalamic dysfunction, hypoventilation, and
autonomic dysregulation; all required artificial ventila-
tion; and 15 (43 %) developed tumours of neural crest
origin. Copy number variation (CNV) analysis by array
comparative genomic hybridization (CGH), using the
Nimblegen 720 k platform, in 26 of the 35 ROHHAD
patients did not identify any ROHHAD-specific CNVs.
Table 1 reveals a slight gender bias within our cohort
(21 females, 14 males), however in our extensive
experience studying ROHHAD we have not identified
any specific gender prevalence, and careful review of
ROHHAD referrals subsequent to this study identified
equal distribution of females and males in our broader
ROHHAD cohort.
Exome sequencing
WES was completed on a total of 31 individuals includ-
ing 16 ROHHAD patients (7 as part of trios in the dis-
covery cohort and 9 in the replication cohort), 15
unaffected relatives (parents and one monozygotic twin),
and tumour samples from four of the ROHHAD pro-
bands (Table 2).
De novo inheritance model - trio analysis
To identify de novo variants, we sequenced the exomes of
seven ROHHAD trios. In this set of exomes, we achieved
130-fold mean coverage (after mapping and removal of
PCR duplicate reads) with an average of 91.8 % +/− 0.81 %
(SD) of bases covered at least 20-fold (Table 2). Using
DeNovoGear [15] to analyze the trios, 13 candidate de
novo variants were identified and validated by Sanger ana-
lysis (Table 3). Each patient carried between zero and
three exonic or UTR de novo variants (average 1.86 per
exome; 0.71 amino acid altering per exome), a value that
is consistent with previous findings [28] and the expected
mutation rate [29]. However, no two of these seven ROH-
HAD patients had de novo variants in the same gene.
In a second iteration of the genetic analysis, the 7
ROHHAD trio probands plus 9 additional ROHHAD
exomes were then searched for other candidate vari-
ants (not necessarily de novo) in the 13 genes that
had been flagged as containing de novo variants. Four
genes were identified (C17ORF53, PDE11A, WDFY4,
and FAM199X) that contained de novo variants in one
patient each, and one or more additional candidate vari-
ants (novel or rare [MAF < 0.005] exonic, UTR, or splice
site [within 2 bp of an exon] variants not within a segmen-
tal duplication) in other exomes (Table 4). From these four
genes, C17ORF53 was selected for mutation analysis in
the replication cohort. It was selected because both of the
candidate variants identified among the 16 patient exomes
were amino acid altering, and neither was known to be
inherited (one is known to be de novo; there was no inher-
itance information for the other). Although four different
rare variants were identified among five patients in
PDE11A, it was not selected for mutation analysis because
in two cases, the variant was inherited from clinically un-
affected parents, while another variant resulted in a syn-
onymous change. WDFY4 and FAM199X were each
mutated in two individuals, but they were not considered
for mutation analysis as, in both cases, one variant was
shown to be inherited while the other variant resulted in a
synonymous change.
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Somatic mutation model (tumour and MZ twin analysis)
It is possible that de novo mutations giving rise to ROH-
HAD may be so severe that they are normally incompat-
ible with life. Such a mechanism has been hypothesized
for mutations in AKT1, which cause the Proteus syn-
drome, but have only been found in a mosaic state and
never in all somatic cells [9]. Similarly, surviving patients
with ROHHAD may be mosaic for the disease-causing
mutation, carried in only a subset of their cells and tissues.
If this model were applicable, the subset of ROHHAD pa-
tients with neural crest tumours would be the most likely
to have an identifiable mutation, and the tumours them-
selves would be the most likely tissue to carry the causa-
tive mutation. To test this somatic mutation hypothesis,
we sequenced the exomes of tumours from four of the
seven patients that were included in the trio analysis.
We assumed that the tumour samples would contain
a variable amount of normal non-tumourous tissue.
Because this mosaic state would reduce our ability to de-
tect rare mutations, we increased the sequencing cover-
age to approximately double that obtained from the
trios. This achieved a mean coverage of 260-fold (after
mapping and removal of PCR duplicate reads) with an
average of 95.1 % +/− 0.54 % (SD) of targeted bases cov-
ered at least 20-fold (Table 2). Since each analyzed
tumour sample came from a ROHHAD case in a trio,
DeNovoGear [15] was used to compare the tumour sam-
ples to the parental samples. Any de novo variants iden-
tified in a tumour were then compared to the de novo
variants identified in that patient’s genomic DNA to sin-
gle out any de novo variants unique to the tumour. All
13 of the de novo variants identified in the trio analysis
were also present in the corresponding tumours; how-
ever, no additional tumour-only variants were detected.
Our cohort also contains a pair of monozygotic (MZ)
twins discordant for the ROHHAD phenotype [30]. To
evaluate the possibility of somatic mosaicism for a causa-
tive mutation in the affected twin, we used DeNovoGear
to compare the variant profile between the twins, but did
not identify any sequence variants in the affected twin’s
exome that were not also present in the unaffected twin.
Autosomal recessive model
To identify potential recessive candidates, the trios were
used to identify genes containing compound heterozygous
inherited rare coding variants (or homozygous, as long as
each parent was carrying the variant). We identified be-
tween one and four compound heterozygous candidate
genes in each patient. These are genes that contained two
rare variants inherited in trans (i.e., one from each parent)
(Table 5). No individual compound heterozygous candidate
was seen in more than one individual, none of the nine
Table 3 De novo variants observed in the exomes of seven ROHHAD cases (discovery cohort)
Proband ID Gene Selected transcript and
variant effect










21.1 Deleterious (1.000) chr11:60893229




19.84 Neutral (0.006) chr7:80303443




5.791 Neutral (0.085) chr17:42226217
NEK7 NM_133494:c.*2404A > G 3′UTR 12.83 N/A chr1:198291053









29.7 Deleterious (0.999) chr20:37529233
TAF1 NM_004606:c.4356C >
T:p.R1452=
Synonymous 14.37 N/A chrX:70627913
Patient 41 PDE11A NM_001077358:c.783C >
T:p.D261=
Synonymous 11.94 N/A chr2:178592832
FAM155B NM_015686:c.*652G > A 3'UTR 1.311 N/A chrX:68750448
Patient 42 PLCXD3 NM_001005473:c.*9191 T > C 3'UTR 4.216 N/A chr5:41311356
Patient 45 CCT4 NM_006430:c.*613G > A 3'UTR 4.916 N/A chr2:62095797
WDFY4 NM_020945:c.8577G >
T:p.T2859=
Synonymous 1.393 N/A chr10:50174711
FAM199X NM_207318:c.828C >
T:p.S276=
Synonymous 15.08 N/A chrX:103432819
All variants are heterozygous
"*5" indicates the position 5 nucleotides 3' of the translation stop codon
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replication exomes were found to contain two sequence
variants in any of these genes, and none of these candidates
have a known function that would strongly suggest an as-
sociation with ROHHAD. Thus, we have not pursued any
of them further at this time. We acknowledge that, in light
of the fact that ROHHAD may be highly genetically het-
erogeneous, one or more of these genes may indeed be
disease-causing in an individual proband – but further
studies would be required in order to gain additional evi-
dence in support of any particular gene.
Autosomal dominant model
Though a familial dominant inheritance model is not
consistent with the sporadic occurrence of this disease,
we did search the 7 ROHHAD patient exomes for any
genes that contained rare protein-altering (i.e., missense,
nonsense, splice-site and indel) variants in all or a large
subset of the patients after censoring the de novo or
inherited status. After further filtering by visual inspec-
tion in the Integrative Genomics Viewer (IGV; [31, 32]),
multiple variant calls were removed as probable false
positives (e.g. eliminating rare variants on reads that
hosted multiple other rare variants – we assumed that
these reads were poorly mapped). At this stage, we iden-
tified no genes with candidate variants in the same gene
among 4 or more of the 7 patients. We did identify four
genes (FRAS1, RELN, RIF1, POLE) that each had different
rare, protein-altering variants among 3 of the 7 patients
(Table 6). We searched the 9 exomes from the replica-
tion cohort for rare protein-altering variants in these
four genes and identified only one additional patient
with a candidate variant in RIF1 (Table 6). All four of
the RIF1 variants were validated by Sanger sequencing.
All four RIF1 variants as well as all variants in the three







MAF (Minor allele count/total










PDE11A chr2:178592832 Synonymous NM_001077196:
c.525C>T:p.D175D
Not found; Not Found;
0.000016 (2/122254)


























Not found; Not found; Not
found



















chr17:44162274 3′ UTR NM_001171251:
c.*342C > G





WDFY4 chr10:50174711 Synonymous NM_020945:
c.8577G >
T:p.T2859=
Not found; Not found; Not
found











FAM199X chrX:103432819 Synonymous NM_207318:
c.828C >
T:p.S276=
Not found; Not found; 0.000024
(3/122866)
15.08 N/A Patient 45 De novo
chrX:103435332 3'UTR NM_207318:
c.*876C > G
Not found; Not found; Not
found
3.885 N/A Patient 18 Inherited (and
present in MZ
twin)
aAll 16 ROHHAD exomes were searched for candidate variants (as described in methods: novel or rare (MAF < 0.005) exonic, UTR, or splice site (within 2 bp of an
exon) variants not within a segmental duplication) within the 13 genes identified as containing de novo variants in one ROHHAD proband
b1000 Genomes Project (http://www.1000genomes.org); EVS = Exome Variant Server (http://evs.gs.washington.edu/EVS/); ExAC = Exome Aggregation
Consortium (http://exac.broadinstitute.org)
c Of these four genes, C17ORF53 was selected for mutation analysis in an additional 19 ROHHAD patients. One additional sequence variant was identified through
this analysis, and is represented in the bolded row
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Table 5 Compound heterozygous variants observed in exomes of seven ROHHAD cases (discovery cohort)
Proband
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genes in which three of 16 probands have candidate
variants (FRAS1, RELN, POLE), were inherited from
unaffected parents, with both maternal and paternal
transmission (Table 6).
Additionally, 187 genes were identified with poten-
tial variants in 2 of the 7 discovery cohort patients
(Additional file 2), but these have not been inspected
in IGV, and a portion of them are likely false positive
calls. While it remains possible that sequence variants
in one or more of these genes are causative of ROH-
HAD, with such a large number of candidate genes,
and without inheritance information to support any
particular one, it presently remains difficult to obtain
enough genetic evidence to identify one as a causative
gene. In one attempt to narrow down this list, we
looked only at loss-of-function (LOF) variants, but
did not identify any gene with LOF variants in more
than one proband.
Structural variation analysis
In addition to identifying SNVs and small indels (as de-
scribed in the previous sections), we also analyzed the
ROHHAD exome data (including the tumour samples)
for larger variations such as chromosomal transloca-
tions and inter chromosomal insertions and CNVs. No
CNVs and no exonic translocations or insertions were
detected in any of the samples. However, with exome
data alone, we cannot rule out the possibility of fusion
events in intronic or intergenic regions.
Mutation analysis
We performed mutation analysis (by Sanger sequencing)
of two candidate genes (C17ORF53 and MAPKAPK5) in
19 additional ROHHAD patients.
C17ORF53
In total, we identified three novel or rare (MAF < 0.005)
variants in a search of the exons and UTRs of the
C17ORF53 gene among 35 ROHHAD patients (16 by ex-
ome sequencing and 19 by Sanger sequencing) (Table 4).
Two were non-synonymous variants, and one was in the
3’UTR. We do not have genetic samples from the parents
of two of the patients carrying sequence variants in this
gene, and so are unable to determine whether or not they
are de novo variants. Since very little is known about the
protein encoded by this open reading frame, we do not
have information to model the effect these sequence vari-
ants would have. Further investigation into the protein
(when and where it is expressed, and what its function is)
and the effect of these variants would be required to fur-
ther implicate them in ROHHAD.
MAPKAPK5
Improvement in a subset of phenotypic features in Pa-
tient 27 was observed shortly after a regimen of caffeine
treatment (100 mg BID) was initiated [33]. A study
found that transcript levels of MAPKAPK5 (in which Pa-
tient 27 is carrying a de novo missense variant; Table 3)
were transiently increased in response to forskolin
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treatment (which, like caffeine, elevates cAMP) [34],
leading us to hypothesize that MAPKAPK5 might be in-
volved in this patient’s ROHHAD phenotype. However,
mutation analysis in our ROHHAD cohort did not iden-
tify any additional novel or rare exonic, splice site, or
UTR sequence variants in MAPKAPK5.
Discussion
Our hypothesis that ROHHAD might be caused by
germline de novo mutations or by mosaicism for somatic
mutation(s) in one or more genes was tested using seven
trios, including neural crest tumours of four of these pa-
tients and the unaffected MZ twin of one (Table 2), as
well as an additional 28 singleton ROHHAD patients
used for mutation analysis of candidate genes. Despite
the homogeneity of this ROHHAD cohort, and the depth
of coverage established in our exome sequencing, we did
not identify any two patients who had de novo variants in
the same gene, any de novo coding variants unique to the
tumours, or any variants discordant between the affected
and unaffected MZ twins. We also did not identify any
structural variations in the exomes. While the sporadic oc-
currence of ROHHAD suggests a de novo inheritance
model, we were also able to use the exome sequencing
data to assess autosomal recessive and autosomal domin-
ant inheritance models. Neither model revealed a major
gene that would explain ROHHAD in our cohort. One or
more of the genes containing a) de novo variants (Table 3,
Table 4), b) inherited compound heterozygous variants
(Table 5), or c) inherited heterozygous variants in 3 or 4
patients (Table 6), may be causative of ROHHAD in some
cases, but further genetic and/or functional evidence is
Table 6 Genes with candidate variants observed in three of seven ROHHAD cases
Gene Proband
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required before these variants could be considered truly
pathogenic for the ROHHAD phenotype. In particular, it
is difficult to determine the significance of the RIF1 find-
ing (that 4 of 16 patients have inherited a rare protein-
altering variant in this gene). The gene is large (41 exons
encoding 2472 amino acids), and harbours a substantial
number of variants (2492 variants in the ExAC database
[20], 937 of which are rare protein-altering variants, and
20 of which are loss-of-function (LOF) variants [i.e.,
nonsense, frameshift, or canonical splice site mutations]).
Thus, additional evidence - genetic (i.e., identifying add-
itional ROHHAD patients with RIF1 mutations) or func-
tional (i.e., discovering a RIF1 function that could explain
the ROHHHAD phenotype) – would be required to prove
that this is more than a random chance occurrence. An in
silico search using Ingenuity Pathway Analysis (Qiagen)
for functional connections among these 31 genes did not
identify any potential links between different candidate
genes from more than two patients.
Previous studies postulated eight genes (NDN, ASCL1,
PHOX2B, NTRK2, BDNF, HTR1A, OTP, and ADCYAP1)
as candidate ROHHAD genes, based on their roles in
the development or function of the systems (hypothal-
amic, autonomic, and neuroendocrine) known to be
deficient in ROHHAD, but failed to identify any disease-
associated variants in these genes among their cohorts
[2, 4, 13]. Likewise, we did not identify any candidate vari-
ants in any of these eight genes in our 7 ROHHAD patient
exomes (for each gene, at least 96 % of the coding bases
were covered at least 20-fold with the exception of OTP,
for which one of three exons was not effectively captured),
confirming that none of these eight genes is a major
ROHHAD gene. A recent study described a novel non-
sense mutation in the Smith-Magenis gene, RAI1, in a pa-
tient previously diagnosed with ROHHAD (though the
authors note that deeper evaluation revealed his pheno-
type was not consistent with ROHHAD or Smith-Magenis
syndrome) [35]. We did not identify any candidate vari-
ants in RAI1 in our 7 ROHHAD patient exomes, despite
the fact that >96 % of coding bases were covered at least
20-fold, suggesting that mutations in this gene are not
characteristic of ROHHAD.
Although the present analysis did not uncover a causa-
tive gene for ROHHAD, it does not completely rule out
the possibility that ROHHAD is caused by de novo coding
mutations. There are several aspects of the disease that
may lead our analysis, as currently designed, to miss a de
novo coding answer, even if one exists. For one, the possi-
bility that somatic mosaicism represents the major mech-
anism for ROHHAD complicates our analysis in that we
may not have sampled the major tissue(s) carrying the
ROHHAD-causing mutations, such as the brainstem or
hypothalamic nuclei. Our use of the patients’ neuroendo-
crine tumours represents one approach to addressing this
challenge, because these tissues would be expected to con-
tain the causative ROHHAD genetic lesion if one exists.
The fact that we did not identify any coding mutations
distinct to the tumours suggests that the genetic lesion(s)
we are looking for may be rare and highly specific (such as
regulatory mutations or fusion genes) or are located out-
side the exonic region. Secondly, there is the possibility
that ROHHAD is characterized by a high level of genetic
heterogeneity, whereby a discovery set of seven probands
is not sufficiently large to contain more than one patient
with a mutation in any single ROHHAD gene. However,
we think that this is unlikely, as we did extend our exome
analysis to include a total of 16 ROHHAD patients, and
our entire study cohort included a total of 35 ROHHAD
patients, suggesting that exome sequencing of additional
trios or individuals is not likely to lead to an answer for
the underlying genetics of ROHHAD. Finally, some limita-
tions remain as to what can be discovered, even within
the coding region, by WES. The mutations causing
ROHHAD may be of a nature that is difficult to detect by
WES, such as triplet repeat expansion. Alternatively,
causative mutations might have occurred in parts of genes
poorly enriched by our capture kit, and thus not covered
by our sequencing. A list of those genes reveals several
genes with known functions that could potentially be
linked to ROHHAD; those will require a more extensive
follow up sequencing project.
Given the many recent successes of WES in identifying
disease-causing mutations, our study represents a major
effort toward discovering the cause of ROHHAD. Though
no coding pathogenic mutations for this disease were
identified, our experimental design was sufficiently robust
for us to conclude that exome sequencing of trios and tu-
mours is not likely to be an efficient means of identifying
the cause of ROHHAD. A reasonable next step would be
whole genome sequencing to look for de novo mutations
beyond the coding exome, that may disrupt promoter re-
gions, transcription factor binding sites, microRNA genes
or binding sites, or other important non-coding regions.
It is also important to consider alternative hypotheses
wherein ROHHAD may not have a genetic etiology.
Older literature has suggested that ROHHAD may be a
paraneoplastic condition, resulting from pathophysiology
triggered by a specific subset of neuroendocrine tumours
[6, 36, 37]. Nevertheless, the fact that many patients with
ROHHAD do not have neuroendocrine tumours sug-
gests that the paraneoplastic hypothesis cannot be the
single unifying model. Similarly, the fact that patients
whose tumours were removed do not experience remis-
sion of other symptoms, and the ROHHAD phenotype
continues to evolve with advanced hypoventilation and
autonomic dysregulation, makes this model less attractive
as an explanation. An autoimmune etiology for ROHHAD
has also been postulated [6, 38, 39] though it is not clear
Barclay et al. Orphanet Journal of Rare Diseases  (2015) 10:103 Page 11 of 13
that all the study subjects actually had ROHHAD, or that
the intervention modified the phenotype. No technology
yet available can rule out an autoimmune etiology for a
particular disease, though autoimmune-mediated inflam-
mation cannot explain a predisposition to neoplasia.
Conclusion
Using a comprehensive, well-designed and carefully exe-
cuted exome sequencing study in an expertly-phenotyped
cohort of 35 ROHHAD patients, we were not able to
identify de novo pathogenic mutations causing ROHHAD.
Our findings suggest that clinical exome sequencing is
unlikely to be a useful diagnostic test in patients with
true ROHHAD. However, because ROHHAD is a dev-
astating disease that is characterized by a high inci-
dence of cardiorespiratory arrest in childhood and by
the need for artificial ventilation for life-support, it re-
mains imperative to refine the search for genetic risk
factors for ROHHAD, as well as to investigate other
possible mechanisms of disease.
Additional files
Additional file 1: Low-coverage proportions of candidate genes in
replication exomes. (XLSX 43 kb)
Additional file 2: Genes carrying putative candidate mutations in 2
of 7 ROHHAD probands in the discovery cohort. (XLSX 44 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SFB designed the study, planned and carried out the bioinformatic data
analysis, designed and performed variant validations, designed mutation
analysis, led data interpretation, and drafted and revised the paper. CMR
designed the study, assisted with case designation, collected and extracted
DNA from tissue samples, assisted with data interpretation, and drafted and
revised the paper. LAB and LN designed and performed variant validations
and mutation analyses, and revised the draft paper. PAG conceived the initial
study, and contributed to the design of the overall study, assisted with data
interpretation, and revised the draft paper. RJAW designed the study,
assisted with data interpretation, and revised the draft paper. WTG designed
the study, assisted with clinical assessments/case designation, assisted with
data interpretation, and revised the draft paper. PMKG performed exome
sequence alignments, assisted with planning bioinformatics analyses,
designed and performed structural variation analyses, and revised the draft
paper. ZA wrote scripts for bioinformatic data analysis and revised the draft
paper. EMB-K and DI-L assisted with clinical assessments/case designation,
assisted with data interpretation, and revised the draft paper. DEW-M
initiated the international collaboration and continues to serve as its leader,
conceived and designed the study, clinically assessed all patients, led the
interpretation of clinical data/case designation, assisted with genetics data
interpretation, and drafted and revised the paper. NTB-H designed and
planned the study, led and supervised genetic analyses, assisted with data
interpretation and drafted and revised the paper. All authors read and
approved the final manuscript.
Acknowledgments
Funding for the exome and Sanger sequencing at the ACHRI Genomic and
Bioinformatic Platform and UCDNA Services, University of Calgary was
generously provided by ROHHAD Fight, Inc. SFB, NTBH, RJAW, CMR and
DEW-M were also funded, in part, by ROHHAD Fight, Inc. SFB is also funded
by the ACHRI-CIHR Training Program. NTBH is also funded by CIHR. PAG is
funded by NIH HL089742. RJAW is funded by AIHS and CIHR. WTG is funded
by the CFRI and the CIHR. Sincere thanks to Richard Pon for his assistance in
designing and planning the exome sequencing experiments. The authors
would like to thank the Exome Aggregation Consortium and the groups that
provided exome variant data for comparison. A full list of contributing
groups can be found at http://exac.broadinstitute.org/about.
Author details
1Department of Medical Genetics, Cumming School of Medicine, Alberta
Children’s Hospital Research Institute, University of Calgary, Calgary, AB,
Canada. 2Center for Autonomic Medicine in Pediatrics (CAMP) in Department
of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago and
Stanley Manne Children’s Research Institute, Chicago, IL, USA. 3Department
of Anatomy and Neurobiology, Washington University of Medicine, St Louis,
MO, USA. 4Department of Medical Genetics, University of British Columbia
and Child & Family Research Institute, Vancouver, B.C., Canada. 5Department
of Physiology and Pharmacology, Alberta Children’s Hospital Research
Institute and Hotchkiss Brain Institute, Cumming School of Medicine,
University of Calgary, Calgary, AB, Canada. 6Departments of Pediatrics,
Neurological Sciences, and Biochemistry, Rush University Medical Center,
Chicago, IL, USA. 7Department of Pediatrics, Division of Pediatric
Endocrinology, University of Illinois at Chicago, Chicago, IL, USA.
8Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Received: 3 July 2015 Accepted: 29 July 2015
References
1. Fishman LS, Samson JH, Sperling DR. Primary alveolar hypoventilation
syndrome (Ondine’s Curse). Am J Dis Child. 1965;110:155–61.
2. Ize-Ludlow D et al. Rapid-onset obesity with hypothalamic dysfunction,
hypoventilation, and autonomic dysregulation presenting in childhood.
Pediatrics. 2007;120(1):E179–88.
3. Bougneres P et al. Endocrine manifestations of the rapid-onset obesity with
hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor
syndrome in childhood. J Clin Endocrinol Metab. 2008;93(10):3971–80.
4. De Pontual L et al. Delineation of late onset hypoventilation associated with
hypothalamic dysfunction syndrome. Pediatr Res. 2008;64(6):689–94.
5. Onal H, Ersen A. A case of late-onset central hypoventilation syndrome with
hypothalamic dysfunction: through a new phenotype. Turk J Pediatr.
2010;52(2):198–202.
6. Paz-Priel I, Cooke DW, Chen AR. Cyclophosphamide for rapid-onset obesity,
hypothalamic dysfunction, hypoventilation, and autonomic dysregulation
syndrome. J Pediatr. 2011;158(2):337–9.
7. Weese-Mayer DE et al. An official Ats clinical policy statement: congenital
central hypoventilation syndrome: genetic basis, diagnosis, and
management. Am J Respir Crit Care Med. 2010;181(6):626–44.
8. Douglas J et al. Nsd1 mutations are the major cause of sotos syndrome and
occur in some cases of weaver syndrome but are rare in other overgrowth
phenotypes. Am J Hum Genet. 2003;72(1):132–43.
9. Lindhurst MJ et al. A mosaic activating mutation in Akt1 associated with the
Proteus syndrome. N Engl J Med. 2011;365(7):611–9.
10. Kurek KC et al. Somatic mosaic activating mutations in Pik3ca Cause Cloves
syndrome. Am J Hum Genet. 2012;90(6):1108–15.
11. Gibson WT et al. Mutations in Ezh2 cause Weaver syndrome. Am J Hum
Genet. 2012;90(1):110–8.
12. Weksberg R et al. Beckwith-Wiedemann syndrome demonstrates a role for
epigenetic control of normal development. Hum Mol Genet. 2003;12 Spec
No 1:R61–8.
13. Rand CM et al. Rapid-onset obesity with hypothalamic dysfunction,
hypoventilation, and autonomic dysregulation: analysis of hypothalamic and
autonomic candidate genes. Pediatr Res. 2011;70(4):375–8.
14. Beaulieu CL et al. Forge Canada consortium: outcomes of A 2-year national
rare-disease gene-discovery project. Am J Hum Genet. 2014;94(6):809–17.
15. Ramu A et al. Denovogear: De Novo Indel and point mutation discovery
and phasing. Nat Methods. 2013;10(10):985–7.
16. Van Der Auwera, GA, et al. From Fastq Data To High Confidence Variant
Calls: The Genome Analysis Toolkit Best Practices Pipeline. Current Protocols
In Bioinformatics/Editoral Board, Andreas D. Baxevanis et al. 2013. 11(1110):
11 10 1–11 10 33.
Barclay et al. Orphanet Journal of Rare Diseases  (2015) 10:103 Page 12 of 13
17. Wang K, Li M, Hakonarson H. Annovar: functional annotation of genetic
variants from high-throughput sequencing data. Nucleic Acids Res.
2010;38(16):E164.
18. Abecasis GR et al. An integrated map of genetic variation from 1,092
human genomes. Nature. 2012;491(7422):56–65.
19. Exome Variant Server, Nhlbi Go Exome Sequencing Project (Esp), Seattle,
Wa. December, 2014. Available From: Http://Evs.Gs.Washington.Edu/Evs/.
20. Exome Aggregation Consortium (Exac), Cambridge, Ma. Available From:
http://exac.broadinstitute.org.
21. Kircher M et al. A general framework for estimating the relative
pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310–5.
22. Adzhubei IA et al. A method and server for predicting damaging missense
mutations. Nat Methods. 2010;7(4):248–9.
23. Hayes M, Li J. Bellerophon: a hybrid method for detecting
interchromosomal rearrangements at base pair resolution using next-
generation sequencing data. BMC Bioinformatics. 2013;14 Suppl 5:S6.
24. Shi Y, Majewski J. Fishingcnv: a graphical software package for detecting
rare copy number variations in exome-sequencing data. Bioinformatics.
2013;29(11):1461–2.
25. Ye J et al. Primer-blast: a tool to design target-specific primers for
polymerase chain reaction. BMC Bioinformatics. 2012;13:134.
26. Li H, Durbin R. Fast and accurate short read alignment with
burrows-wheeler transform. Bioinformatics. 2009;25(14):1754–60.
27. Langmead B et al. Ultrafast and memory-efficient alignment of short Dna
sequences to the human genome. Genome Biol. 2009;10(3):R25.
28. O’roak BJ et al. Exome sequencing in sporadic autism spectrum disorders
identifies severe de novo mutations. Nat Genet. 2011;43(6):585–9.
29. Lynch M. Rate, molecular spectrum, and consequences of human mutation.
Proc Natl Acad Sci U S A. 2010;107(3):961–8.
30. Patwari PP et al. Monozygotic twins discordant for Rohhad phenotype.
Pediatrics. 2011;128(3):E711–5.
31. Robinson JT et al. Integrative genomics viewer. Nat Biotechnol.
2011;29(1):24–6.
32. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer
(Igv): high-performance genomics data visualization and exploration. Brief
Bioinform. 2013;14(2):178–92.
33. Gordon, SC, et al. The evolving phenotype in a patient with Rapid-Onset
Obesity With Hypothalamic Dysfunction, Hypoventilation, And Autonomic
Dysregulation (Rohhad) and response to caffeine treatment. Am J Respir
Crit Care. 2015. Med(191): P. A5923, 2015 - Presented At American Thoracic
Society International Conference, Denver, Co, May 2015.
34. Gerits N et al. The transcriptional regulation and cell-specific expression of
the Mapk-activated protein kinase Mk5. Cell Mol Biol Lett. 2009;14(4):548–74.
35. Thaker VV et al. Whole exome sequencing identifies rai1 mutation in a
morbidly obese child diagnosed with rohhad syndrome. J Clin Endocrinol
Metab. 2015;100(5):1723–30.
36. Ouvrier R et al. Idiopathic hypothalamic dysfunction: a paraneoplastic
syndrome? Lancet. 1995;346(8985):1298.
37. Sirvent N et al. Hypothalamic dysfunction associated with neuroblastoma:
evidence for a new paraneoplastic syndrome? Med Pediatr Oncol.
2003;40(5):326–8.
38. Sartori S et al. Intrathecal synthesis of oligoclonal bands in rapid-onset
obesity with hypothalamic dysfunction, hypoventilation, and autonomic
dysregulation syndrome: new evidence supporting immunological
pathogenesis. J Child Neurol. 2014;29(3):421–5.
39. Chow C et al. Rapid-Onset Obesity with Hypothalamic Dysfunction,
Hypoventilation, and Autonomic Dysregulation (Rohhad) syndrome may
have a hypothalamus-periaqueductal gray localization. Pediatr Neurol.
2015;52(5):521–5. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Barclay et al. Orphanet Journal of Rare Diseases  (2015) 10:103 Page 13 of 13
